Trillium Health Care Products Strengthens Leadership Team and Expands Liquid Manufacturing Capacity to Accelerate Growth

BROCKVILLE, ON, June 2, 2025 /PRNewswire/ -- Trillium Health Care Products ("Trillium"), a leading contract development and manufacturing organization (CDMO) of branded over-the-counter ("OTC") products in North America, today announced the appointment of three new seasoned executives -- Michael Pignatiello, Martin Quesnel, and Sherif Elkholy – and the completion of a major expansion of its liquid and semi-solid manufacturing capabilities. These leadership and manufacturing enhancements position Trillium for its next phase of growth and market leadership. 

Michael Pignatiello joins Trillium as Chief Executive Officer.  Michael previously served as Chief Operating Officer of Care/of (owned by Bayer) and held various executive roles at Bayer, including Global Head of External Manufacturing and Pipeline Supply Strategy, where he developed commercial relationships with OTC CDMOs globally. Prior to Bayer, Michael spent 14 years at Merck, where he last served as Operations Leader for Merck Consumer Care.

Martin Quesnel, who has been named Chief Operating Officer, brings more than 35 years of pharmaceutical industry experience, previously serving as General Manager, Canada for Catalent and holding various executive roles at Accucaps and Jones Healthcare Group. Prior to Catalent, Martin spent 23 years at GlaxoSmithKline (GSK), where he served in senior leadership positions across the company.

Joining as Chief Financial Officer, Sherif Elkholy brings a strong financial leadership background to Trillium from his time as Director of Finance at Arnprior Aerospace and his senior finance roles at Radius Global Supply and ORBCOMM and Pfizer Pharmaceuticals.

The new management team's collective experience will play a pivotal role in the execution of a number of key initiatives at Trillium to accelerate long-term growth and better position the business as a market leading North American consumer health CDMO. One such initiative includes the recent buildout of its new liquid and semi-solid expansion facility. The facility features a brand new 5,900 square foot GMP liquids and semi-solids suite, and state-of-the-art 10,000L integrated high-shear manufacturing tanks to support the efficient production of some of Trillium's fastest-growing brands. The new investments will add meaningful manufacturing capacity in liquids and semi-solids while utilizing best-in-class technology, making Trillium one of the leading providers of both dosage forms in North America.

Looking ahead, Trillium is actively evaluating strategic acquisitions to expand its geographic footprint across North America and provide further access for its customers to new product technologies.

Trillium Health Care Products is backed by Avista Healthcare Partners, a leading private equity firm focused exclusively on healthcare with over $8 billion invested in more than 45 growth-oriented healthcare businesses globally. Avista has been one of the most active investors in the consumer healthcare sector over the last decade, having completed over 20 investments in brands and supply chain services businesses across North America and Western Europe.

"We are excited to welcome Mike, Marty and Sherif to the team," said Alex Yu, Partner at Avista. "Their knowledge of the consumer healthcare and pharmaceutical sectors, deep operational backgrounds, and unique perspectives as former CDMO customers will be instrumental in executing our growth strategy and elevating Trillium as a best-in-class operator and industry leader."

About Trillium Health Care Products

Trillium Health Care Products is a leading contract development and manufacturing organization (CDMO) of branded OTC products in North America. Trillium is a trusted partner to leading global consumer healthcare and pharmaceutical companies, with broad capabilities across liquid, semi-solid and solid dosage forms. For more information about Trillium, visit https://trilliumhcp.com/.

About Avista Healthcare Partners

Founded in 2005, Avista Healthcare Partners is a leading New York-based private equity firm with over $9 billion invested in 50 growth-oriented healthcare businesses globally. Avista partners with businesses that feature strong management teams, stable cash flows and robust growth prospects – targeting healthcare product and technology businesses with clear scale potential across six sub-sectors experiencing strong tailwinds. The team is supported by a group of seasoned Strategic Executives enhancing the entire investment process through strategic insight, long-term value and sustainable businesses. For more information, visit www.avistahealthcare.com or follow Avista on LinkedIn.

For media inquiries, please contact:
Daniel Yunger / William Halliday
Kekst CNC
[email protected] / [email protected]
917.574.8582 / 917.842.2709

SOURCE Avista Healthcare Partners